CN117285468A - Ensitrelvir中间体的制备方法 - Google Patents
Ensitrelvir中间体的制备方法 Download PDFInfo
- Publication number
- CN117285468A CN117285468A CN202310749885.4A CN202310749885A CN117285468A CN 117285468 A CN117285468 A CN 117285468A CN 202310749885 A CN202310749885 A CN 202310749885A CN 117285468 A CN117285468 A CN 117285468A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- chloro
- methyl
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- -1 2-chloro-5- ((methylamino) methyl) -4-nitroaniline Chemical compound 0.000 claims abstract description 32
- YRZNRFJEBAPCCO-UHFFFAOYSA-N Cn1cc2cc(N)c(Cl)cc2n1 Chemical compound Cn1cc2cc(N)c(Cl)cc2n1 YRZNRFJEBAPCCO-UHFFFAOYSA-N 0.000 claims abstract description 8
- HETBKLHJEWXWBM-UHFFFAOYSA-N 4-chloro-3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(C=O)=CC=C1Cl HETBKLHJEWXWBM-UHFFFAOYSA-N 0.000 claims abstract description 7
- QMPBBNUOBOFBFS-UHFFFAOYSA-N 6-[(6-chloro-2-methylindazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione Chemical compound CN1N=C(C=C(C(/N=C(\NC(N2CC3=NN(C)C=N3)=O)/N(CC(C=C(C(F)=C3)F)=C3F)C2=O)=C2)Cl)C2=C1 QMPBBNUOBOFBFS-UHFFFAOYSA-N 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- JBQSGXPHZOCDTI-UHFFFAOYSA-N 2-chloro-5-(methylaminomethyl)aniline Chemical compound CNCC1=CC=C(Cl)C(N)=C1 JBQSGXPHZOCDTI-UHFFFAOYSA-N 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 abstract description 19
- 239000007858 starting material Substances 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- 238000006193 diazotization reaction Methods 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 238000007069 methylation reaction Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 abstract description 2
- 238000004440 column chromatography Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 abstract description 2
- 238000007670 refining Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- CHLANRNBFOWJBG-UHFFFAOYSA-N 6-chloro-2-methyl-5-nitroindazole Chemical compound ClC=1C(=CC2=CN(N=C2C1)C)[N+](=O)[O-] CHLANRNBFOWJBG-UHFFFAOYSA-N 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 7
- 239000012346 acetyl chloride Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical group CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical group CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical group CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical group COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- OKOSGBYZOWWAPH-UHFFFAOYSA-N 5-chloro-2-methyl-4-nitroaniline Chemical compound CC1=CC([N+]([O-])=O)=C(Cl)C=C1N OKOSGBYZOWWAPH-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 241001528534 Ensifer Species 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
- C07C209/32—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups
- C07C209/325—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups reduction by other means than indicated in C07C209/34 or C07C209/36
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种Ensitrelvir中间体的制备方法,该方法包括:式VI化合物2‑氯‑5‑((甲胺基)甲基)‑4‑硝基苯胺经反应,得到式VII化合物6‑氯‑2‑甲基‑2H‑吲唑‑5‑胺。本发明技术方案使用容易得到且更加廉价的4‑氯‑3硝基苯甲醛作为起始原料,采用更安全的反应操作,避免使用水合肼等有毒有害试剂,制备总收率更高的新冠口服药Ensitrelvir的重要中间体6‑氯‑2‑甲基‑2H‑吲唑‑5‑胺及其相应的盐,避免使用重氮化以提高反应的安全性,避免使用异构体分离纯化以提高中间体的产率,避免对异构体进行甲基化反应以提高中间体的产率,降低了制备和工业化生产的成本,且后处理精制不需要柱层析。
Description
[技术领域]
本发明涉及药物合成领域,具体涉及一种Ensitrelvir中间体的制备方法。
[背景技术]
6-氯-2-甲基-2H-吲唑-5-胺及其相应的盐是新冠口服药物恩赛特韦(Ensitrelvir)的重要中间体。Ensitrelvir是由日本盐野义公司研制并用于新冠治疗。
6-氯-2-甲基-2H-吲唑-5-胺
现有报道的6-氯-2-甲基-2H-吲唑-5-胺及其相应的盐的合成方法主要使用5-氯-2-甲基-4-硝基苯胺作为起始物料,通过重氮化反应构建吲唑环,再经过甲基化反应和还原反应制备。
该合成路线存在重氮化安全隐患、甲基化反应区域选择性差、异构体分离纯化困难、总收率较低和工业生产成本较高等缺点。
[发明内容]
为了解决上述问题,本发明公开一种Ensitrelvir中间体的制备方法,这种方法使用了简单易得的原料,成本低,操作安全,Ensitrelvir重要中间体的总收率高,工业生产成本较低。
本发明的技术方案如下:
一种Ensitrelvir中间体的制备方法,包括以下步骤:
(1)式VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺经反应,得到式VII化合物6-氯-2-甲基-2H-吲唑-5-胺。
进一步地,还包括:
(2)式III化合物2-氯-5-((甲胺基)甲基)-苯胺经反应,得到式VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺。
进一步地,所述步骤(2)包括:
(2-1)式III化合物2-氯-5-((甲胺基)甲基)-苯胺经反应,得到式IV化合物;
(2-2)式IV化合物经反应,得到式VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺;
其中,R为H、烷基、卤代烷基、芳香基、芳杂环基、
进一步地,所述步骤(2-1)式III化合物溶于有机溶剂中,加入碱性试剂,滴加溶液,反应。优选的,碱性试剂如三乙胺。
进一步地,所述步骤(2-2)包括:
(2-2-1)式IV化合物经反应,得到式V化合物;
(2-2-2)式V化合物经取代反应,脱保护基得到VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺。
进一步地,所述步骤(2-2-1)式III化合物溶于浓硫酸中,冰浴降温,缓慢滴加浓硝酸,控温反应。
进一步地,所述步骤(2-2-2)式III化合物溶于有机溶剂中,加入盐酸,反应。
进一步地,所述步骤(1)式VI化合物溶于有机溶剂中,加入锌粉和甲酸铵,反应。
进一步地,所述式III化合物2-氯-5-((甲胺基)甲基)-苯胺由式II化合物1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐溶于有机溶剂中,然后加入水,铁粉和氯化铵,反应制备得到,
进一步地,所述式II化合物1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐由式I化合物4-氯-3硝基苯甲醛溶于有机溶剂中,加入甲胺水溶液,反应制备得到,
进一步地,所述式I化合物4-氯-3硝基苯甲醛由式I化合物4-氯-3硝基苯甲醛由VIII化合物4-氯苯甲醛溶于浓硫酸中,冰浴降温,缓慢滴加浓硝酸,控温反应制备得到,
与现有技术相比,本发明具有以下技术效果:
使用容易得到且更加廉价的4-氯-3硝基苯甲醛作为起始原料,采用更安全的反应操作,避免使用水合肼等有毒有害试剂,制备总收率更高的新冠口服药Ensitrelvir的重要中间体6-氯-2-甲基-2H-吲唑-5-胺及其相应的盐,避免使用重氮化以提高反应的安全性,避免使用异构体分离纯化以提高中间体的产率,避免对异构体进行甲基化反应以提高中间体的产率,降低了制备和工业化生产的成本,且后处理精制不需要柱层析。
[具体实施例]
为进一步阐述本发明所采取的技术手段及其效果,以下结合实施例对本发明作进一步地说明。可以理解的是,此处所描述的具体实施方式仅仅用于解释本发明,而非对本发明的限定。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1:1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐的合成
向三口瓶内加入4-氯-3硝基苯甲醛(107.8mmol,1eq,20g)和甲醇(100mL),搅拌使其溶解,冰浴降温至10℃以下,然后滴加40%甲胺水溶液(161.7mmol,1.5eq,12.5g),滴加过程中控温不超过20℃。滴毕,继续于冰浴下搅拌反应2小时。然后再分批加入硼氢化钠(80.8mmol,0.75eq,3.1g),加入过程中控温不超过20℃。加完后继续于冰浴下搅拌反应0.5小时。LCMS监测原料后,加入100ml水终止反应,减压浓缩除去甲醇,水相用乙酸乙酯(100ml*3)萃取三次,合并有机相,减压浓缩得粗品。将粗品再溶于100ml乙酸乙酯中,用浓盐酸调节pH≈1,析出固体,过滤,滤饼用乙酸乙酯20ml淋洗一次,真空干燥得黄色固体1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐23.5g,收率:92%。LCMS(ESI)m/z=201.1
[M+H]+.1H NMR(400MHz,DMSO-d6)δ9.75(s,2H),8.34(d,J=1.9Hz,1H),7.94(dd,J=8.3,2.0Hz,1H),7.86(d,J=8.3Hz,1H),4.22(s,2H),2.52(s,3H)。
实施例2:2-氯-5-((甲胺基)甲基)-苯胺的合成
向三口烧瓶中加入1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐(99.1mmol,1eq,23.5g)和95%乙醇(70ml),搅拌使其溶解,再加入水(30ml),升温至80℃,然后再分批加入铁粉(396.5mmol,4eq,22.1g)和氯化铵。加完后继续于80℃搅拌4小时。LCMS监测原料后,趁热垫硅藻土过滤,滤饼用95%乙醇(50ml*2)搅拌洗涤两次,减压浓缩除去乙醇,然后再向残留中加入50ml水,用乙酸乙酯(50ml*3)萃取三次,合并有机相,饱和食盐水(50ml)洗涤一次,无水硫酸钠干燥,过滤,减压浓缩得黄色粘稠液体2-氯-5-((甲胺基)甲基)-苯胺15.4g,收率:91%。LCMS(ESI)m/z=171.1[M+H]+.1H NMR(400MHz,CDCl3)δ7.16(d,J=8.1Hz,1H),6.74(d,J=2.0Hz,1H),6.61(dd,J=8.1,2.0Hz,1H),4.04(brs,2H),3.62(s,2H),2.42(s,3H),1.76(brs,1H)。
实施例3:N-(3-乙酰胺基-4-氯苄基)-N-甲基乙酰胺的合成
向三口烧瓶中加入2-氯-5-((甲胺基)甲基)-苯胺(90.2mmol,1eq,15.4g)和二氯甲烷(50ml),搅拌使其溶解,再加入三乙胺(225.6mmol,2.5eq,22.8g),冰浴下滴加乙酰氯(198.2mmol,2.2eq,15.5g)的二氯甲烷(30ml)溶液。滴加过程中控温不超过20℃。滴毕,冰浴下继续搅拌反应2小时。LCMS监测原料后,加入50ml水淬灭反应,用6M盐酸调节pH≈1,分液,水相用二氯甲烷(50ml)萃取一次,合并有机相,饱和食盐水(50ml)洗涤一次,无水硫酸钠干燥,过滤,减压浓缩得类白色固体N-(3-乙酰胺基-4-氯苄基)-N-甲基乙酰胺21.4g,收率:93%。LCMS(ESI)m/z=255.1[M+H]+.1H NMR(400MHz,CDCl3)δ8.19(d,J=2.0Hz,1H),7.64(brs,1H),7.28(d,J=8.0Hz,1H),6.93(dd,J=8.0,2.0Hz,1H),4.53(s,2H),2.94(s,3H),2.22(s,3H),2.14(s,3H)。
实施例3中酰化剂乙酰氯可用正丁酰氯、异丁酰氯、氯甲酸甲酯、氯甲酸乙酯代替。
实施例4:N-(5-乙酰胺基-4-氯-2硝基苄基)-N-甲基乙酰胺的合成
将N-(3-乙酰胺基-4-氯苄基)-N-甲基乙酰胺(84.0mmol,1eq,21.4g)溶于浓硫酸(60ml)中,降温至-10℃以下,缓慢滴加65%硝酸(168.0mmol,2eq,16.3g),滴加过程中控温不超过-5℃。滴毕,继续于-5℃以下搅拌反应6小时。LCMS监测原料后,将反应体系缓慢倒入100ml冰水中,析出固体,过滤,滤饼用冰水(20ml)淋洗一次,真空干燥得淡黄色固体N-(5-乙酰胺基-4-氯-2硝基苄基)-N-甲基乙酰胺21.7g,收率:86%。LCMS(ESI)m/z=300.1[M+H]+。1H NMR(400MHz,CDCl3)δ8.48(s,1H),8.25(s,1H),7.85(brs,1H),4.98(s,2H),3.16(s,3H),2.29(s,3H),2.28(s,3H)。
实施例5:2-氯-5-((甲胺基)甲基)-4-硝基苯胺的合成
将N-(5-乙酰胺基-4-氯-2硝基苄基)-N-甲基乙酰胺(72.4mmol,1eq,21.7g)溶于95%乙醇(100ml)中,加入2M盐酸水溶液(100ml),升温至回流搅拌反应24小时。LCMS监测原料后,减压浓缩除去乙醇,水相用乙酸乙酯(50ml*2)萃取两次,然后用饱和碳酸钠将水相调节pH≈9,再用乙酸乙酯(50ml*3)萃取三次,合并有机相,饱和食盐水(50ml)洗涤一次,无水硫酸钠干燥,过滤,减压浓缩得淡黄色粘稠液体2-氯-5-((甲胺基)甲基)-4-硝基苯胺13.9g,收率:89%。LCMS(ESI)m/z=216.1[M+H]+。1H NMR(400MHz,DMSO-d6)δ
8.05(s,1H),7.04(s,1H),6.81(s,2H),3.91(s,2H),3.17(s,1H),2.32(s,3H)。
实施例6:6-氯-2-甲基-5-硝基-2H-吲唑的合成
将2-氯-5-((甲胺基)甲基)-4-硝基苯胺(64.5mmol,1eq,13.9g)溶于甲醇(100ml)中,加入锌粉(322.5mmol,5eq,20.9g),冰浴下滴加甲酸铵(64.5mmol,1eq,4.1g)溶于甲醇(50ml)的溶液,滴加过程中控温不超过20℃,滴毕,室温搅拌反应过夜。反应结束后,垫硅藻土过滤,滤饼用甲醇(10ml)淋洗一次,合并有机相,减压浓缩,残留物用乙酸乙酯/正庚烷=1:4(v/v)重结晶得淡黄色固体6-氯-2-甲基-5-硝基-2H-吲唑8.8g,收率:75%。LCMS(ESI)m/z=182.1[M+H]+;1H NMR(400MHz,CDCl3)δ7.69(s,1H),7.62(s,1H),6.89(s,1H),4.13(s,3H);13C NMR(400MHz,CDCl3)δ145.1,137.6,124.4,121.8,121.4,117.4,100.7,40.2。
实施例3-1:N-(4-氯-3-丙酰胺基苄基)-N-甲基丙酰胺的合成
向三口烧瓶中加入2-氯-5-((甲胺基)甲基)-苯胺(58.6mmol,1eq,17.0g)和二氯甲烷
(40ml),搅拌使其溶解,再加入三乙胺(146.5mmol,2.5eq,14.8g),冰浴下滴加丙酰氯(128.9mmol,2.2eq,15.5g)的二氯甲烷(30ml)溶液。滴加过程中控温不超过20℃。滴毕,冰浴下继续搅拌反应2小时。LCMS监测原料后,加入50ml水淬灭反应,用6M盐酸调节pH≈1,分液,水相用二氯甲烷(50ml)萃取一次,合并有机相,饱和食盐水(50ml)洗涤一次,无水硫酸钠干燥,过滤,减压浓缩得淡黄色粘稠油状物N-(4-氯-3-丙酰胺基苄基)-N-甲基丙酰胺14.9g,收率:90%。LCMS(ESI)m/z=282.11[M+H]+。
实施例4-1:N-(4-氯-2-硝基-3-丙酰胺基苄基)-N-甲基丙酰胺的合成
将N-(4-氯-3-丙酰胺基苄基)-N-甲基丙酰胺(54.0mmol,1eq,15.2g)溶于浓硫酸(40ml)中,降温至-10℃以下,缓慢滴加65%硝酸(108.0mmol,2eq,10.5g),滴加过程中控温不超过-5℃。滴毕,继续于-5℃以下搅拌反应8小时。LCMS监测原料后,将反应体系缓慢倒入100ml冰水中,析出固体,过滤,滤饼用冰水(20ml)淋洗一次,真空干燥得淡黄色固体N-(4-氯-2-硝基-3-丙酰胺基苄基)-N-甲基丙酰胺14.7g,收率:83%。LCMS(ESI)m/z=327.1[M+H]+。
实施例5-1:2-氯-5-((甲胺基)甲基)-4-硝基苯胺的合成
将N-(4-氯-2-硝基-3-丙酰胺基苄基)-N-甲基丙酰胺(49.2mmol,1eq,16.1g)溶于95%乙醇(70ml)中,加入2M盐酸水溶液(70ml),升温至回流搅拌反应24小时。LCMS监测原料后,减压浓缩除去乙醇,水相用乙酸乙酯(50ml*2)萃取两次,然后用饱和碳酸钠将水相调节pH≈9,再用乙酸乙酯(50ml*3)萃取三次,合并有机相,饱和食盐水(50ml)洗涤一次,无水硫酸钠干燥,过滤,减压浓缩得淡黄色粘稠液体2-氯-5-((甲胺基)甲基)-4-硝基苯胺8.93g,收率:84%。LCMS(ESI)m/z=216.1[M+H]+。
其中,实施例3用乙酰氯参与反应时,6-氯-2-甲基-5-硝基-2H-吲唑的总收率为44.7%。
其中,实施例3-1用丙酰氯参与反应时,6-氯-2-甲基-5-硝基-2H-吲唑的总收率为39.4%。
当实施例3中的乙酰氯用正丁酰氯代替时,6-氯-2-甲基-5-硝基-2H-吲唑的总收率为37.5%。
当实施例3中的乙酰氯用异丁酰氯代替时,6-氯-2-甲基-5-硝基-2H-吲唑的总收率为33.1%。
当实施例3中的乙酰氯用氯甲酸甲酯代替时,6-氯-2-甲基-5-硝基-2H-吲唑的总收率为42.8%。
当实施例3中的乙酰氯用氯甲酸乙酯代替时,6-氯-2-甲基-5-硝基-2H-吲唑的总收率为38.5%。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (12)
1.一种Ensitrelvir中间体的制备方法,其特征在于:包括以下步骤:
(1)式VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺经反应,得到式VII化合物6-氯-2-甲基-2H-吲唑-5-胺。
2.根据权利要求1所述的制备方法,其特征在于:还包括:
(2)式III化合物2-氯-5-((甲胺基)甲基)-苯胺经反应,得到式VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺。
3.根据权利要求2所述的制备方法,其特征在于:所述步骤(2)包括:
(2-1)式III化合物2-氯-5-((甲胺基)甲基)-苯胺经反应,得到式IV化合物;
(2-2)式IV化合物经反应,得到式VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺;
其中,R为H、烷基、卤代烷基、芳香基、芳杂环基、
4.根据权利要求3所述的制备方法,其特征在于,所述步骤(2-1)式III化合物溶于有机溶剂中,加入碱性试剂,滴加溶液,反应。
5.根据权利要求3所述的制备方法,其特征在于:所述步骤(2-2)包括:
(2-2-1)式IV化合物经反应,得到式V化合物;
(2-2-2)式V化合物经取代反应,脱保护基得到VI化合物2-氯-5-((甲胺基)甲基)-4-硝基苯胺。
6.根据权利要求5所述的制备方法,其特征在于,所述步骤(2-2-1)式IV化合物溶于浓硫酸中,冰浴降温,缓慢滴加浓硝酸,控温反应;
所述步骤(2-2-2)式V化合物溶于有机溶剂中,加入盐酸,反应。
7.根据权利要求1至6中任意一项所述的制备方法,其特征在于,所述步骤(1)式VI化合物溶于有机溶剂中,加入锌粉和甲酸铵,反应。
8.根据权利要求2至6中任意一项所述的制备方法,其特征在于:所述式III化合物2-氯-5-((甲胺基)甲基)-苯胺由式II化合物1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐溶于有机溶剂中,然后加入水,铁粉和氯化铵,反应制备得到,
9.根据权利要求8所述的制备方法,其特征在于:所述式II化合物1-(4-氯-3-硝基苯基)-N-甲基甲胺盐酸盐由式I化合物4-氯-3硝基苯甲醛溶于有机溶剂中,加入甲胺水溶液,反应制备得到,
10.通式化合物Ⅳ,
其中,R为H、烷基、卤代烷基、芳香基、芳杂环基、
11.通式化合物Ⅴ,
其中,R为H、烷基、卤代烷基、芳香基、芳杂环基、
12.化合物Ⅵ,
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022107330647 | 2022-06-26 | ||
CN202210733064 | 2022-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117285468A true CN117285468A (zh) | 2023-12-26 |
Family
ID=89247016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310749885.4A Pending CN117285468A (zh) | 2022-06-26 | 2023-06-25 | Ensitrelvir中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117285468A (zh) |
-
2023
- 2023-06-25 CN CN202310749885.4A patent/CN117285468A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6061158B2 (ja) | 6−(7−((1−アミノシクロプロピル)メトキシ)−6−メトキシキノリン−4−イルオキシ)−n−メチル−1−ナフトアミド、またはそれの薬学的に許容される塩の合成中間体およびその使用 | |
CN111646922B (zh) | 一种2-(4-溴-2-氰基-6-氟苯基)乙酸的合成方法 | |
CN107857743B (zh) | 一种制备盐酸罗沙替丁醋酸酯及中间体的方法 | |
US2811555A (en) | Reduction of 2-nitroso-5-diethylaminotoluene | |
CN110590635A (zh) | 左乙拉西坦及其中间体的制备方法 | |
US6657085B2 (en) | Process for the preparation of aniline compounds | |
CN117285468A (zh) | Ensitrelvir中间体的制备方法 | |
CN116283629A (zh) | 一种5-氨基-2硝基苯甲酸的制备方法 | |
KR100574350B1 (ko) | 2-아미노피리딘 유도체의 제조방법 | |
CN113861167A (zh) | 富马酸伏诺拉生的制备方法 | |
CN117285469A (zh) | 恩赛特韦中间体的制备方法 | |
CN112272665A (zh) | 制备立他司特的方法 | |
CN116874411B (zh) | 一种1-溴咔唑的合成方法 | |
CN117126108A (zh) | 一种Ensitrelvir中间体的制备方法 | |
JPH1059917A (ja) | C−h−酸化合物のニトロソ化方法 | |
CN102491954B (zh) | 利奈唑胺的制备方法 | |
US4794182A (en) | 2-Alkyl-4-amino-5-aminomethylpyrimidines | |
CN117229216A (zh) | 一种恩赛特韦中间体的制备方法 | |
JPH072742A (ja) | 4−アミノ−3−メチル−N−エチル−N−(β−ヒドロキシエチル)アニリン硫酸塩の新規製造法 | |
KR100730766B1 (ko) | 비페닐아세트산의 신규 제조방법 | |
WO2001019779A1 (en) | Preparation of halogenated primary amines | |
US5475140A (en) | Process for producing N,N-disubstituted p-phenylenediamine derivative sulfate | |
JP3700190B2 (ja) | 2−インダニルメチルアミンの製造法並びにn−ベンジル−n−(2−インダニルメチル)アミン及びその製造法 | |
TW202104164A (zh) | 製造經取代之2-[2-(苯基)乙胺]烷醯胺衍生物之方法 | |
CN112679410A (zh) | 一种罗本考昔中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |